Weight Loss Clinic in Oadby

What are GLP-1 weight loss injections?

GLP-1 receptor agonists — Mounjaro (tirzepatide) and Wegovy (semaglutide) being the two licensed for weight management in the UK — are weekly self-injection medications that act on appetite-regulating hormones. They were originally developed for type 2 diabetes (under the names Ozempic and Mounjaro) and re-licensed at higher doses for weight management after pivotal trials showed sustained, clinically significant weight loss.

For Oadby and Wigston residents, these medications are available through NHS Tier 3 / Tier 4 weight-management services or via private prescription. NHS access is tightly rationed and typically involves waiting lists of 12–24 months, with strict BMI and comorbidity thresholds. Most adults who meet the NICE eligibility criteria (BMI 30+, or 27.5+ with a weight-related comorbidity) but want to start within weeks rather than years go private.

How do Mounjaro and Wegovy work?

Both drugs mimic GLP-1, a hormone naturally released after eating that signals fullness to the brain and slows stomach emptying. Mounjaro additionally acts on GIP (glucose-dependent insulinotropic polypeptide), a second appetite-regulating hormone — it's a dual GLP-1/GIP agonist. In practice, this means:

• You feel full sooner, on smaller meals.
• You feel hungry less often between meals.
• Food cravings (especially for high-calorie, high-reward foods) reduce significantly for most people.
• Stomach emptying slows, prolonging satiety.

Neither drug forces weight loss — they make eating less feel easy rather than constantly fought against. Real-world effectiveness depends on alongside-treatment behaviour: physical activity, protein intake, sleep, and not undoing the effect with liquid calories.

Mounjaro vs Wegovy: which is right for me?

In direct head-to-head trials, Mounjaro tends to produce greater average weight loss than Wegovy:

• Mounjaro at full dose (15mg weekly) — SURMOUNT-1 trial showed average 21% body-weight reduction over 72 weeks.
• Wegovy at full dose (2.4mg weekly) — STEP-1 trial showed average 15% body-weight reduction over 68 weeks.

But these are averages; individual response varies hugely. Some patients respond better to Wegovy than Mounjaro. Tolerability also differs — the side-effect profiles overlap but aren't identical, and an Independent Prescriber can switch you between products if one isn't working.

Other factors that influence the choice:

• Cost — Mounjaro is currently slightly more expensive per month at most doses.
• Dose escalation schedule — both have a 4-month ramp-up to reach maintenance dose.
• Storage — Mounjaro KwikPen is shelf-stable for 30 days at room temperature once started; Wegovy is similar.

Who is eligible? The NICE BMI criteria

NICE recommends GLP-1 weight-management treatment for adults who meet specific BMI thresholds:

For South Asian, Black African and Black Caribbean populations — a significant proportion of Leicester and Oadby residents — NICE recommends adjusted lower BMI thresholds (BMI 27.5 instead of 30) because cardiovascular risk emerges at lower BMI in these populations. We follow the most recent NICE adjustments at every consultation.

What to expect: month-by-month

Weeks 1–4 (starter dose, 2.5mg Mounjaro / 0.25mg Wegovy)

Modest appetite reduction. Some patients experience nausea, particularly in the first 3–5 days after each injection — worse with high-fat or large meals. Constipation, indigestion, occasional headache. Modest weight loss (1–3kg).

Weeks 5–8 (5mg / 0.5mg)

Appetite reduction more pronounced. Most early side effects begin to settle. Weight loss accelerates (typically 1–2kg per week for first month, then slowing).

Months 3–6 (escalating doses up to maintenance)

Dose continues to step up to maintenance level (15mg Mounjaro / 2.4mg Wegovy). Cumulative weight loss typically 5–12% body weight by month 6. Side effects largely settled. Energy levels and clothes-fit changes become noticeable.

Months 6–12 (maintenance phase)

Weight loss continues but plateaus toward end of year 1. Many patients hit 15–20% total weight loss by month 12. This is when the medication's effect on metabolic markers — HbA1c, blood pressure, cholesterol — shows up in routine bloods.

Side effects: the full picture

Most common (>10% of patients):

• Nausea — especially weeks 1–4, usually settles. Smaller, lower-fat meals help.
• Indigestion / heartburn — slower stomach emptying. Antacids help if needed.
• Constipation — hydration and fibre intake matter more on GLP-1s.
• Diarrhoea — less common than constipation but possible.

Less common but worth knowing:

• Gallbladder problems — rapid weight loss increases gallstone risk; we monitor for symptoms.
• Pancreatitis — rare but documented. Severe abdominal pain that persists is a red flag — stop the medication, contact us.
• Thyroid effects — rodent studies showed thyroid tumour risk; no confirmed human signal but contraindicated in people with personal or family history of medullary thyroid cancer or MEN-2 syndrome.
• Injection site reactions — redness, swelling, itching. Usually mild.

Full prescribing information is available from the eMC Summary of Product Characteristics for Mounjaro KwikPen and the equivalent Wegovy SmPC.

What about stopping treatment?

Weight regain is the honest concern with GLP-1 treatment — trials show patients regain ~two-thirds of lost weight within a year of stopping unless they've embedded lasting behavioural changes (diet pattern, physical activity, sleep). This isn't a flaw of the drug, it's how appetite regulation works — the medication suppresses appetite while you take it; appetite returns when you stop.

The strategy that works: use GLP-1 treatment as a window to embed habits that survive without it. Strength training to preserve muscle mass during weight loss; protein-forward eating; structured eating windows; resolving sleep debt. Then taper off rather than stopping abruptly, ideally with continuing review.

Lifestyle alongside treatment

GLP-1 medications work best alongside, not instead of, lifestyle changes. The most evidence-backed interventions:

• Strength training 2–3x per week — preserves muscle mass during weight loss, maintains resting metabolic rate.
• Protein at every meal — 0.8–1.2g per kg target weight per day. Helps satiety, preserves muscle.
• Walking — 7,500–10,000 steps daily is achievable on appetite-suppressed days; lower-impact than running and easier to sustain.
• Sleep — less than 7 hours raises appetite-stimulating ghrelin. Worth getting right.

How much does private treatment cost in Oadby?

Pricing varies by dose. We charge for the medication only — your initial consultation, every monthly review, the injection demonstration, and the GLP-1 prescription itself are all included. We'll give you the full monthly figure (medication + any extras) at the consultation. There's no subscription lock-in, no auto-billing, and no contract — stop the moment you reach your goal or anytime before.

NHS Tier 3 vs private: the honest comparison

NHS Tier 3 weight-management services are excellent when you can access them, and free. They include dietitian support, group education, and — in some cases — access to GLP-1 prescribing. The catch is waiting time: most Tier 3 services have 12–24 month waiting lists, with strict BMI thresholds (typically 35+, or 32.5+ with comorbidity). If you fit those criteria and are happy to wait, ask your GP about referral first.

For everyone else — BMI between 27.5 and 34.9, or unable to wait — private is the practical route. We're not in competition with the NHS; we're a complementary access point for people the NHS pathway doesn't currently reach quickly.